Javascript must be enabled to continue!
Timing of vitrectomy for treatment of endophthalmitis after intravitreal anti-VEGF injection: a systematic literature review of case reports and series
View through CrossRef
Objective:
To perform a systematic literature review analyzing visual outcomes of immediate, early, and delayed vitrectomy in the treatment of acute endophthalmitis after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections.
Methods:
We conducted a literature search using the Ovid Medline, Embase.com, and Web of Science databases, and relevant articles were selected from original English papers published from 2005 to 2021. Inclusion criteria were studies reporting cases of acute post-anti-VEGF endophthalmitis, defined as occurring within 6 weeks of injection treatment. Exclusion criteria were pediatric cases and cases explicitly reported to be caused by injections of contaminated drugs. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal tool for case reports and case series. The study dataset for descriptive and statistical analysis comprised patient-level data extracted from included studies. The timing of vitrectomy compared were defined as (1) immediate vitrectomy as occurring within 24 h of endophthalmitis diagnosis; (2) early vitrectomy as occurring between 24 and 48 h of endophthalmitis diagnosis; (3) late vitrectomy as occurring after 48 h of endophthalmitis diagnosis. Primary outcome was final visual acuity following treatment with vitrectomy.
Results:
Twenty-five articles were published that met our inclusion and exclusion criteria for a total of 86 cases. Thirty-seven were immediate vitrectomy, 25 were early, and 24 were late vitrectomy treatment groups, respectively. We observed differences in final visual outcomes and in improvement from diagnosis to final visual acuity, with patients receiving immediate and late vitrectomy to have better final visual outcomes than those patients receiving early vitrectomy ( p < 0.005).
Conclusion:
Our results show that there may be an association between time to vitrectomy and visual outcomes. Immediate and late vitrectomy treatment groups had better visual outcomes than the early group. Our results were limited by the reliance on case reports and series and the paucity of data available specifying the timing of vitrectomy. Additional research is necessary to elucidate the effects of treatment timing in patients with endophthalmitis following anti-VEGF injection.
Title: Timing of vitrectomy for treatment of endophthalmitis after intravitreal anti-VEGF injection: a systematic literature review of case reports and series
Description:
Objective:
To perform a systematic literature review analyzing visual outcomes of immediate, early, and delayed vitrectomy in the treatment of acute endophthalmitis after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections.
Methods:
We conducted a literature search using the Ovid Medline, Embase.
com, and Web of Science databases, and relevant articles were selected from original English papers published from 2005 to 2021.
Inclusion criteria were studies reporting cases of acute post-anti-VEGF endophthalmitis, defined as occurring within 6 weeks of injection treatment.
Exclusion criteria were pediatric cases and cases explicitly reported to be caused by injections of contaminated drugs.
Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal tool for case reports and case series.
The study dataset for descriptive and statistical analysis comprised patient-level data extracted from included studies.
The timing of vitrectomy compared were defined as (1) immediate vitrectomy as occurring within 24 h of endophthalmitis diagnosis; (2) early vitrectomy as occurring between 24 and 48 h of endophthalmitis diagnosis; (3) late vitrectomy as occurring after 48 h of endophthalmitis diagnosis.
Primary outcome was final visual acuity following treatment with vitrectomy.
Results:
Twenty-five articles were published that met our inclusion and exclusion criteria for a total of 86 cases.
Thirty-seven were immediate vitrectomy, 25 were early, and 24 were late vitrectomy treatment groups, respectively.
We observed differences in final visual outcomes and in improvement from diagnosis to final visual acuity, with patients receiving immediate and late vitrectomy to have better final visual outcomes than those patients receiving early vitrectomy ( p < 0.
005).
Conclusion:
Our results show that there may be an association between time to vitrectomy and visual outcomes.
Immediate and late vitrectomy treatment groups had better visual outcomes than the early group.
Our results were limited by the reliance on case reports and series and the paucity of data available specifying the timing of vitrectomy.
Additional research is necessary to elucidate the effects of treatment timing in patients with endophthalmitis following anti-VEGF injection.
Related Results
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical activi...
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Refractive status and ocular characteristics of preschool children with retinopathy of prematurity after different treatments
Refractive status and ocular characteristics of preschool children with retinopathy of prematurity after different treatments
AIM: To compare the changes in preschool refractive status, ocular biological parameters, and higher-order aberrations in children with retinopathy of prematurity (ROP) after retin...
Comparative efficacy and safety of Faricimab with other intravitreal anti-vascular endothelial growth factor in the treatment of Neovascular age related macular degeneration- A Systematic review and meta-analysis.
Comparative efficacy and safety of Faricimab with other intravitreal anti-vascular endothelial growth factor in the treatment of Neovascular age related macular degeneration- A Systematic review and meta-analysis.
Age-related macular degeneration (AMD) is the leading cause of visual impairment in patients age 50 and older, with an estimated 200 million people affected worldwide. The neovascu...
The Auckland Endophthalmitis Study
The Auckland Endophthalmitis Study
Purpose: To report on the incidence and management of endophthalmitis following intravitreal bevacizumab in Auckland, New Zealand. Method: A survey of facilities in Auckland perfor...
COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB
COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB
Purpose:
To determine whether sterile preloading of anti–vascular endothelial growth factor agents reduces the risk of postintravitreal injection endophthalmitis.
...
Role of intravitreal/intracameral antibiotics to prevent traumatic endophthalmitis – Meta-analysis
Role of intravitreal/intracameral antibiotics to prevent traumatic endophthalmitis – Meta-analysis
Traumatic endophthalmitis is a devastating condition that can occur following an open globe injury and result in loss of vision. The use of prophylactic antibiotics is empirical as...
Incidence Rates of Endophthalmitis after Various Pharmaceutical Intravitreal Injections
Incidence Rates of Endophthalmitis after Various Pharmaceutical Intravitreal Injections
Introduction: The purpose of this study is to analyze incidence rates of endophthalmitis after intravitreal injection(s) of bevacizumab (BEVA), brolucizumab (BROL), aflibercept (AF...

